NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | MicrobiomeTrials← Back to trialsNCT06239272
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-03-27Est. Completion: 2034-06
Enrollment target: 139 participants Locations- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Our Lady of the Lake Children's Hospital, Baton Rouge, Louisiana, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University Medical Center, St Louis, Missouri, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Other microbiome trials you might be interested in
Retroperitoneal SarcomaLiposarcomaDedifferentiated Liposarcoma
This phase I trial tests the safety, side effects, and best dose of abemaciclib and how well it works with radiation the…
Seattle, United StatesEst. completion Mar 3, 2027
Advanced LeiomyosarcomaAdipocytic SarcomaAdvanced Liposarcoma
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved …
St Louis, United StatesEst. completion May 31, 2031